Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder

References

• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–14; discussion 1314–5. doi:10.1016/j.eururo.2006.09.019
   Web of Science ®Google Scholar
• Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760–766. doi:10.1046/j.1464-410x.2001.02228.x
   PubMed Web of Science ®Google Scholar
• D’Ancona C, Haylen B, Oelke M, et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn. 2019;38(2):433–477. doi:10.1002/nau.23897
   PubMed Web of Science ®Google Scholar
• Agarwal A, Eryuzlu LN, Cartwright R, et al. What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol. 2014;65(6):1211–1217. doi:10.1016/j.eururo.2014.01.019
   PubMed Web of Science ®Google Scholar
• Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20. doi:10.1002/nau.20798
   PubMed Web of Science ®Google Scholar
• Abrams P, Kelleher CJ, Kerr LA, et al. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6(11 Suppl):S580–90.
   PubMed Web of Science ®Google Scholar
• Teunissen D, van Weel C, Lagro-Janssen T. Urinary incontinence in older people living in the community: examining help-seeking behaviour. Br J Gen Pract. 2005;55(519):776–782.
   Web of Science ®Google Scholar
• NICE UK. Urinary Incontinence: The Management of Urinary Incontinence in Women (CG40). NICE UK; 2006.
   Google Scholar
• Wagg A, Gibson W, Ostaszkiewicz J, et al. Urinary incontinence in frail elderly persons: report from the 5th International Consultation on Incontinence. Neurourol Urodyn. 2015;34(5):398–406. doi:10.1002/nau.22602
   PubMed Web of Science ®Google Scholar
• Allison SJ, Gibson W. Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience. Ther Adv Urol. 2018;10(12):411–419. doi:10.1177/1756287218801282
   PubMed Web of Science ®Google Scholar
• Sacco E, Bientinesi R, Tienforti D, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin Drug Discov. 2014;9(4):433–448. doi:10.1517/17460441.2014.892923
   PubMed Web of Science ®Google Scholar
• Paul Abrams LC, Wagg A, Wein A. Incontinence: 6th International Consultation on Incontinence. Tokyo: ICUD ICS; 2017.
   Google Scholar
• Coyne KS, Wein AJ, Tubaro A, et al. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int. 2009;103(Suppl 3):4–11. doi:10.1111/j.1464-410X.2009.08371.x
   PubMed Web of Science ®Google Scholar
• Shaw C, Cahill J, Wagg A. The current state of continence in Canada: a population representative epidemiological survey. Can J Urol. 2020;27(4):10300–10305.
   Web of Science ®Google Scholar
• Vaughan CP, Johnson TM, Ala-Lipasti MA, et al. The prevalence of clinically meaningful overactive bladder: bother and quality of life results from the population-based FINNO study. Eur Urol. 2011;59(4):629–636. doi:10.1016/j.eururo.2011.01.031
   PubMed Web of Science ®Google Scholar
• Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol. 2006;175(1):191–4; discussion 194–5. doi:10.1016/S0022-5347(05)00067-4
   Web of Science ®Google Scholar
• Shaw C, Wagg A. Overactive bladder in frail older adults. Drugs Aging. 2020;37(8):559–565. doi:10.1007/s40266-020-00777-8
   Web of Science ®Google Scholar
• Smith PP, Kuchel GA, Griffiths D. Functional brain imaging and the neural basis for voiding dysfunction in older adults. Clin Geriatr Med. 2015;31(4):549–565. doi:10.1016/j.cger.2015.06.010
   Web of Science ®Google Scholar
• Komiya H, Umegaki H, Ogama N, et al. Relationships between overactive bladder and cerebral white matter hyperintensity in outpatients at a memory clinic. Geriatr Gerontol Int. 2021;21(11):996–1002. doi:10.1111/ggi.14279
   Web of Science ®Google Scholar
• Sakakibara R, Panicker J, Fowler CJ, et al. Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly. Int J Urol. 2014;21(1):33–38. doi:10.1111/iju.12288
   Web of Science ®Google Scholar
• Elstad EA, Taubenberger SP, Botelho EM, et al. Beyond incontinence: the stigma of other urinary symptoms. J Adv Nurs. 2010;66(11):2460–2470. doi:10.1111/j.1365-2648.2010.05422.x
   Web of Science ®Google Scholar
• Stewart WF, Van Rooyen J, Cundiff G, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–336. doi:10.1007/s00345-002-0301-4
   PubMed Web of Science ®Google Scholar
• Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7(4):455–463. doi:10.1111/j.1524-4733.2004.74008.x
   PubMed Web of Science ®Google Scholar
• Bartoli S, Aguzzi G, Tarricone R. Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review. Urology. 2010;75(3):491–500. doi:10.1016/j.urology.2009.07.1325
   PubMed Web of Science ®Google Scholar
• Chiaffarino F, Parazzini F, Lavezzari M, et al. Impact of urinary incontinence and overactive bladder on quality of life. Eur Urol. 2003;43(5):535–538. doi:10.1016/S0302-2838(03)00097-6
   PubMed Web of Science ®Google Scholar
• Hagglund D, Walker-Engström ML, Larsson G, et al. Quality of life and seeking help in women with urinary incontinence. Acta Obstet Gynecol Scand. 2001;80(11):1051–1055.
   Web of Science ®Google Scholar
• Coyne KS, Zhou Z, Thompson C, et al. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int. 2003;92(7):731–735. doi:10.1046/j.1464-410X.2003.04463.x
   PubMed Web of Science ®Google Scholar
• Barentsen JA, Visser E, Hofstetter H, et al. Severity, not type, is the main predictor of decreased quality of life in elderly women with urinary incontinence: a population-based study as part of a randomized controlled trial in primary care. Health Qual Life Outcomes. 2012;10:153. doi:10.1186/1477-7525-10-153
   Web of Science ®Google Scholar
• Cambronero Santos J, Errando Smet C. Prevalence of storage lower urinary tract symptoms in male patients attending Spanish urology office. Urinary urgency as predictor of quality of life. Actas Urol Esp. 2016;40(10):621–627. doi:10.1016/j.acuro.2016.04.012
   Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388–1395. doi:10.1111/j.1464-410X.2008.07601.x
   PubMed Web of Science ®Google Scholar
• Farage MA, Miller KW, Berardesca E, et al. Psychosocial and societal burden of incontinence in the aged population: a review. Arch Gynecol Obstet. 2008;277(4):285–290. doi:10.1007/s00404-007-0505-3
   Web of Science ®Google Scholar
• Dugan E, Cohen SJ, Bland DR, et al. The association of depressive symptoms and urinary incontinence among older adults. J Am Geriatr Soc. 2000;48(4):413–416. doi:10.1111/j.1532-5415.2000.tb04699.x
   PubMed Web of Science ®Google Scholar
• Johnson TM, Kincade JE, Bernard SL, et al. The association of urinary incontinence with poor self-rated health. J Am Geriatr Soc. 1998;46(6):693–699. doi:10.1111/j.1532-5415.1998.tb03802.x
   PubMed Web of Science ®Google Scholar
• Chiarelli PE, Mackenzie LA, Osmotherly PG. Urinary incontinence is associated with an increase in falls: a systematic review. Aust J Physiother. 2009;55(2):89–95. doi:10.1016/S0004-9514(09)70038-8
   Web of Science ®Google Scholar
• Wilson L, Brown JS, Shin GP, et al. Annual direct cost of urinary incontinence. Obstet Gynecol. 2001;98(3):398–406. doi:10.1016/s0029-7844(01)01464-8
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006;97(1):96–100. doi:10.1111/j.1464-410X.2005.05889.x
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Kopp Z, et al. Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol. 2008;53(5):1029–1037. doi:10.1016/j.eururo.2008.01.027
   PubMed Web of Science ®Google Scholar
• Sexton CC, Coyne KS, Vats V, et al. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care. 2009;15(4 Suppl):S98–S107.
   PubMedGoogle Scholar
• Cassells C, Watt E. The impact of incontinence on older spousal caregivers. J Adv Nurs. 2003;42(6):607–616. doi:10.1046/j.1365-2648.2003.02664.x
   Web of Science ®Google Scholar
• Di Rosa M, Lamura G. The impact of incontinence management on informal caregivers’ quality of life. Aging Clin Exp Res. 2016;28(1):89–97. doi:10.1007/s40520-015-0367-7
   Web of Science ®Google Scholar
• Santini S, Andersson G, Lamura G. Impact of incontinence on the quality of life of caregivers of older persons with incontinence: a qualitative study in four European countries. Arch Gerontol Geriatr. 2016;63:92–101. doi:10.1016/j.archger.2015.10.013
   PubMed Web of Science ®Google Scholar
• Maxwell CJ, Soo A, Hogan DB, et al. Predictors of nursing home placement from assisted living settings in Canada. Can J Aging. 2013;32(4):333–348. doi:10.1017/S0714980813000469
   Web of Science ®Google Scholar
• Morrison A, Levy R. Fraction of nursing home admissions attributable to urinary incontinence. Value Health. 2006;9(4):272–274. doi:10.1111/j.1524-4733.2006.00109.x
   Web of Science ®Google Scholar
• Nuotio M, Tammela TLJ, Luukkaala T, et al. Predictors of institutionalization in an older population during a 13-year period: the effect of urge incontinence. J Gerontol a Biol Sci Med Sci. 2003;58(8):756–762. doi:10.1093/gerona/58.8.M756
   PubMed Web of Science ®Google Scholar
• Avery K, Donovan J, Peters TJ, et al. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn. 2004;23(4):322–330. doi:10.1002/nau.20041
   PubMed Web of Science ®Google Scholar
• Abrams P, Avery K, Gardener N, et al. The international consultation on incontinence modular questionnaire. J Urol. 2006;175(3 Pt 1):1063–6; discussion 1066. doi:10.1016/S0022-5347(05)00348-4
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Cardozo LD, Khullar V, et al. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol. 1997;104(12):1374–1379. doi:10.1111/j.1471-0528.1997.tb11006.x
   PubMedGoogle Scholar
• Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002;11(6):563–574. doi:10.1023/A:1016370925601
   PubMed Web of Science ®Google Scholar
• Coyne KS, Matza LS, Kopp Z, et al. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol. 2006;49(6):1079–1086. doi:10.1016/j.eururo.2006.01.007
   PubMed Web of Science ®Google Scholar
• Abdel-Fattah M, Ramsay I, Barrington JW. A simple visual analogue scale to assess the quality of life in women with urinary incontinence. Eur J Obstet Gynecol Reprod Biol. 2007;133(1):86–89. doi:10.1016/j.ejogrb.2006.04.034
   Web of Science ®Google Scholar
• Volz-Sidiropoulou E, Rings T, Wagg AS, et al. Development and initial psychometric properties of the ‘ICIQ-Cog’: a new assessment tool to measure the disease-related impact and care effort associated with incontinence in cognitively impaired adults. BJU Int. 2018;122(2):309–316. doi:10.1111/bju.14186
   Web of Science ®Google Scholar
• Coyne KS, Matza LS, Thompson CL, et al. Determining the importance of change in the overactive bladder questionnaire. J Urol. 2006;176(2):627–32; discussion 632. doi:10.1016/j.juro.2006.03.088
   PubMed Web of Science ®Google Scholar
• Chapple CR, Cardozo L, Nitti VW, et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33(1):17–30. doi:10.1002/nau.22505
   PubMed Web of Science ®Google Scholar
• Chapple CR, Amarenco G, López Aramburu MA, et al. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn. 2013;32(8):1116–1122. doi:10.1002/nau.22373
   PubMed Web of Science ®Google Scholar
• Chapple CR, Dvorak V, Radziszewski P, et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013;24(9):1447–1458. doi:10.1007/s00192-013-2042-x
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian Phase 3 trial. Eur Urol. 2013;63(2):283–295. doi:10.1016/j.eururo.2012.10.016
   PubMed Web of Science ®Google Scholar
• Nitti VW, Auerbach S, Martin N, et al. Results of a randomized Phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388–1395. doi:10.1016/j.juro.2012.10.017
   PubMed Web of Science ®Google Scholar
• Herschorn S, Barkin J, Castro-Diaz D, et al. A Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82(2):313–320. doi:10.1016/j.urology.2013.02.077
   PubMed Web of Science ®Google Scholar
• Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305. doi:10.1016/j.eururo.2012.10.048
   PubMed Web of Science ®Google Scholar
• Nitti VW, Khullar V, Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013;67(7):619–632. doi:10.1111/ijcp.12194
   PubMed Web of Science ®Google Scholar
• Khullar V, Cambronero J, Angulo J, et al. Age-related efficacy of the selective ß3-adrenoceptor agonist mirabegron for the treatment of overactive bladder (OAB): pooled analysis of three prospective, randomised Phase III studies in patients aged ≥ 65 years. Proceedings of the 42nd annual meeting of the /international Continence Society; 2012:Abstract 331.
   Google Scholar
• Wagg A, Staskin D, Engel E, et al. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a Phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol. 2020;77(2):211–220. doi:10.1016/j.eururo.2019.10.002
   PubMed Web of Science ®Google Scholar
• Malik M, van Gelderen EM, Lee JH, et al. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther. 2012;92(6):696–706. doi:10.1038/clpt.2012.181
   PubMed Web of Science ®Google Scholar
• Tadrous M, Matta R, Greaves S, et al. Association of Mirabegron with the risk of arrhythmia in adult patients 66 years or older-a population-based cohort study. JAMA Intern Med. 2019;179(10):1436–1439. doi:10.1001/jamainternmed.2019.2011
   Web of Science ®Google Scholar
• Wang J, Zhou Z, Cui Y, et al. Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Neurourol Urodyn. 2019;38(1):22–30. doi:10.1002/nau.23863
   Web of Science ®Google Scholar
• Freeman R, Foley S, Rosa Arias J, et al. Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study. Curr Med Res Opin. 2018;34(5):785–793. doi:10.1080/03007995.2017.1419170
   PubMed Web of Science ®Google Scholar
• Chapple CR, Nazir J, Hakimi Z, et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol. 2017;72(3):389–399. doi:10.1016/j.eururo.2017.01.037
   PubMed Web of Science ®Google Scholar
• Foley S, Choudhury N, Huang M, et al. Quality of life in patients aged 65 years and older with overactive bladder treated with mirabegron across eight European countries: secondary analysis of BELIEVE. Int J Urol. 2019;26(9):890–896. doi:10.1111/iju.14050
   Web of Science ®Google Scholar
• Zachariou A, Filiponi M, Kaltsas A, et al. Mirabegron alleviates the degree of burden experienced by caregivers of older females with mixed or urge incontinence: a prospective study. Clin Interv Aging. 2021;16:291–299. doi:10.2147/CIA.S283737
   Web of Science ®Google Scholar